Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Methicillin-resistant Staphylococcus aureus

9 trials tracked for Methicillin-resistant Staphylococcus aureus: 3 in phase 3 or 4.

9Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 1 2 Other / NA 4
  1. Phase 4 Retapamulin for Reducing MRSA Nasal Carriage Completed
  2. Phase 4 Povidone-Iodine for Nasal Decolonization Completed
  3. Phase 3 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Completed
  4. Phase 1 A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers Completed
  5. Phase 1 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers Completed
  6. N/A Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance Completed
Show 3 more trials
  1. N/A Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers Completed
  2. N/A Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) Completed
  3. N/A Active Bathing to Eliminate Infection (ABATE Infection) Trial Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MRSA accounts for 46.4% of S. aureus isolates in Iran, SCCmec III predominates
Infectious Disease Meta-analysis
MRSA accounts for 46.4% of S. aureus isolates in Iran, SCCmec III predominates MRSA Rates In Iran Hit 46 Percent, Review Finds
This meta-analysis of 89 studies estimates pooled MRSA prevalence among human S. aureus isolates in Iran at 46.4%, with SCCmec type III the …
Nearly half of S. aureus samples in Iran were MRSA, a review of 89 studies finds, with hospital-linked strains dominating.
Oct 4, 2026
MRSA carriage prevalence in Ethiopia is 7.3% with high tetracycline resistance at 55.75%
Infectious Disease Meta-analysis
MRSA carriage prevalence in Ethiopia is 7.3% with high tetracycline resistance at 55.75% New data reveals risk factors for MRSA carriage in Ethiopia
This systematic review and meta-analysis of 6,869 individuals in Ethiopia found a pooled MRSA carriage prevalence of 7.3% (95% CI, 5.0-10.8)…
New data identifies how past hospital stays and antibiotic use increase the risk of carrying MRSA in the nose and throat.
Oct 3, 2026
Narrative review discusses CRISPR strategies for MRSA biofilm infections with noted limitations
Infectious Disease Sys. Review
Narrative review discusses CRISPR strategies for MRSA biofilm infections with noted limitations CRISPR could outsmart stubborn staph infections hiding in biofilms
This narrative review examines CRISPR-based strategies targeting resistance genes and virulence factors in Methicillin-resistant Staphylococ…
New CRISPR-based strategies may help break down the protective slime that lets MRSA survive antibiotics, offering hope for hard-to-treat inf…
Frontiers May 13, 2026